Accrued Liabilities

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Accrued Liabilities

Accrued Liabilities

3.Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

	June 30,		December 31,
	2019		2018
Accrued compensation and other payroll liabilities	$	20	$	137
Legal costs		269		106
Accrued interest		—		43
Lease liability		18		—
Other research and development expenses		54		135
Other general and administrative expenses		21		17
Total	$	382	$	438

3. Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

	As of December 31,
	2018		2017
Accrued compensation and other payroll liabilities	$	137	$	306
Legal costs		106		91
Accrued interest		43		38
Other research and development expenses		135		522
Other general and administrative expenses		17		53
Total	$	438	$	1,010

On September 18, 2018, the Company’s Board of Directors approved a workforce reduction involving 5 employees (or 33% of the workforce at that time) to lower costs and conserve cash resources in light of the previously announced request by the FDA for additional pre-clinical data. $0.1 million of unpaid severance costs related to the workforce reduction remained in accrued liabilities as of December 31, 2018 and is included in accrued compensation and other payroll liabilities.